SEC Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. filed a current report on June 4, 2021, regarding executive officer changes effective June 4, 2021. The filing does not report quarterly or annual financial results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating metrics.
Material Changes
- Todd Branning departed as Chief Financial Officer. The filing states that his departure was not related to disagreements concerning operations, financial statements, internal controls, auditors, policies, or practices.
- The Company expects to enter into a separation agreement under which Mr. Branning would be eligible for severance benefits under his employment agreement and could exercise vested stock options through December 31, 2021.
- Anthony Guzzo, the Company’s Vice President and Chief Accounting Officer, was appointed principal accounting officer and interim principal financial officer for Securities Act and Exchange Act filings, effective June 4, 2021.
Compensation, Outlook, and Risks
- Mr. Guzzo’s annual base salary is $337,500, with eligibility for a target annual bonus equal to 30% of base salary, employee benefits, and vacation benefits under Company policies.
- The filing does not provide business guidance, financial outlook, material contingencies, or new operating risks.
- The separation agreement with Mr. Branning was expected but had not yet been finalized in the filing.
Key Facts for Investor Verification
- Confirm the effective dates of Mr. Branning’s departure and Mr. Guzzo’s interim appointment; the filing reports the earliest event date as June 3, 2021, while the personnel changes are stated to be effective June 4, 2021.
- Review the final separation agreement and any resulting severance expense or equity-exercise disclosures.
- Monitor subsequent filings for the appointment of a permanent Chief Financial Officer and principal financial officer.
- Verify that no additional compensation, related-party, internal-control, or financial-statement issues were disclosed in later filings.